ACTU

Actuate Therapeutics Inc (ACTU) SWOT Analysis Analysis (2026)

Invetso Score: 3.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.6 (Moderate)

Net debt remains low at 0.20x EBITDA, which gives ACTU more balance-sheet flexibility than highly levered peers despite weak operating performance.

The current ratio of 1.25x indicates near-term liquidity is adequate, so ACTU is less exposed to refinancing stress than weaker-capitalized competitors.

Cash conversion cycle is reported at zero, suggesting working-capital discipline that can support cash preservation relative to peers with longer conversion cycles.

Weaknesses

Score:

ROIC of -14.9% shows capital is being deployed below cost, leaving ACTU structurally behind profitable peers on value creation.

Leverage is not excessive, but a 0.41x debt-to-equity ratio still constrains flexibility versus stronger peers with cleaner capital structures.

The 1.25x current and quick ratios are only adequate, so ACTU has less liquidity headroom than peers with stronger short-term coverage.

Opportunities

Score:

If ACTU can lift returns from deeply negative ROIC toward peer norms, the largest structural gap in its positioning would narrow materially over the next cycle.

Low net leverage provides room to fund operational improvement or selective investment more easily than peers already burdened by heavier debt loads.

Working-capital efficiency can remain a relative advantage if ACTU sustains a zero cash conversion cycle while peers tie up more cash in operations.

Threats

Score:

Persistently negative ROIC threatens long-term competitiveness because peers with positive returns can reinvest more aggressively and compound market share.

If operating underperformance continues, ACTU may lag peers on capital access and valuation, since weak returns typically compress strategic flexibility.

Liquidity is acceptable but not strong, so any demand shock or margin pressure would leave ACTU less resilient than better-capitalized competitors.

Overall Score

Score:

ACTU’s structural positioning is weak versus peers because deeply negative ROIC outweighs its modest balance-sheet and working-capital advantages.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Actuate Therapeutics Inc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →